Carmat : A capital increase to give financial visibility out to end-2024
>A call on the market of at least € 10m - As expected, Carmat is launching a capital increase with no preferential shareholder subscription rights. With an initial amount of € 10.3m, it may be increased to € 13.6m in the event the extension clause and greenshoe option are fully exercised. The subscription price is € 1.60 per share or a discount of 24.5% to the average weighted share price over the last five trading days –21.2% vs yesterday). The global placement perio...Carmat is focused on the research and development of an innovative product in the medical sector, developing an orthotopic and biocompatible artificial heart which is completely implantable, as well as its electrical power supply system and remote diagnosis system. Co. is developing a long-term therapeutic solution for patients who suffer from advanced bi-ventricular heart failure and who are not eligible for cardiac transplantation and who have exhausted all drug possibilties. Co. is still in the phase of research and development and thus do not generate any revenues.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.